Relevium Medical
Platform injectable gel based therapeutic for osteoarthritis
Relevium Medical is developing an injectable gel for knee osteoarthritis. Approximately half the population will be diagnosed with this pain and progressive disease. Right now, patients have to undergo not only repeat injections to control their pain, but also have to take strong oral medications. Because the disease is progressive and only gets worse over time, many patients end up on highly addictive, high-dose opioids. To date, we have secured $3.7 million in non dilutive funding and completed preclinical testing. We demonstrated that our drug is safe, selectively blocks nerves that transmit pain, and provides pain relief that lasts four times as long. Insurance currently pays $770 per six-monthly treatment for knee osteoarthritis. With 5 million patients in the US, this represents a $7.7 Bn market opportunity. This platform biotherapeutic can also be used to treat other joints affects by osteoarthritis such as the hip and ankle, where the same problems exist in treatment care.
Active Founders
Alison Liddy, Founder
Alison is CEO and Founder at Relevium Medical. Alison holds qualifications in Chemistry and Biochemical Engineering (M.Sc. & Ph.D.). She has worked for major multinational companies including ROCHE, Cook Medical and Boston Scientific; and completed the BioInnovate Fellowship in the prestigious Stanford BioDesign-affiliated program at NUI Galway, Ireland. She is the named inventor on over 20 patent publications and the winner of the Science Foundation of Ireland’s €1 million innovation prize.
Company Launches
ReleviumBio has developed a first-of-a-kind injectable biopharmaceutical for the treatment of knee osteoarthritis (KOA).
The problem: Knee osteoarthritis is a painful and incurable disease that affects millions of people worldwide, yet there has been no disruptive breakthroughs in treatment care in over 50 years, leaving patients heavily reliant on damaging oral medication. The shortcomings of the current injectable treatments leave 2 million US patients reliant on opioids for adequate pain relief. The number one KOA patient complaint is pain, with regenerative therapies to date failing to demonstrate a measurable patient outcome.
Our solution: PeptiFlex is the first injectable therapeutic developed for KOA that gives not only pain relief but also lubricates, and protects the joint.
PeptiFlex is a platform treatment that can be applied to treat other joints affected by osteoarthritis such as the hip and ankle, where the same problems exist in treatment care.
Who are are: Alison and Barry co founders joined forces whilst working at the National University of Galway, Ireland. The partnership was a natural fit with Alison having a strong background in the development and commercialization of life science products, and Dr Barry McDermott having expertise in pharmaceutical development from initial conception up to clinical trial design.
Interested in hearing more: Get in contact at info@Relevium-Medical.com